| Texto completo | |
| Autor(es): |
Moraes, Carla Roberta Peachazepi
;
Saraiva, Camilla Maria de Alencar
;
Borba-Jr, Ivanio Teixeira
;
Duarte, Bruno Kosa Lino
;
de Campos, Paula Melo
;
Saad, Sara Teresinha Olalla
;
De Paula, Erich Vinicius
Número total de Autores: 7
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Hematology, Transfusion and Cell Therapy; v. 48, n. 1, p. 6-pg., 2025-12-19. |
| Resumo | |
Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) marked by a high incidence of coagulopathy. Podoplanin, a glycoprotein involved in platelet activation through interaction with CLEC-2, has recently been identified on leukemic promyelocytes and suggested as a potential contributor to APL coagulopathy. Identification of novel biomarkers and therapeutic targets for APL coagulopathy can potentially improve the outcomes of this condition Aim: To explore whether levels of soluble podoplanin in plasma are different in APL, and to evaluate its association with laboratory and clinical outcomes in these patients Methods: Samples were obtained from consecutive patients with APL at the time of diagnosis in an academic hospital. Biobank samples from 35 patients with non-APL AML matched for age and sex were used as comparators. Circulating podoplanin levels were measured in plasma using a commercial ELISA kit. The study was approved by the institutional ethics committee and all participants provided written informed consent Results: APL patients showed significantly higher plasma soluble podoplanin concentrations compared to non-APL AML. Using the median soluble podoplanin value as a cutoff, a higher proportion of APL patients presented elevated levels. Soluble podoplanin levels correlated with CD40L in APL cases, but not in non-APL AML patients, suggesting a possible interaction with thrombo-inflammatory activation pathways Conclusion: These findings represent a proof-of-concept that measuring soluble podoplanin in plasma samples can contribute to the diagnosis of APL, while also providing novel data on the association of podoplanin with the pathogenesis of APL coagulopathy. (c) 2025 Associa & ccedil;& atilde;o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). (AU) | |
| Processo FAPESP: | 23/03765-0 - Investigação do papel da PDPN na fisiopatologia da coagulopatia na leucemia promielocítica aguda |
| Beneficiário: | Carla Roberta Peachazepi de Moraes |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 22/13216-0 - Interação entre hemostasia e imunidade inata (Imunotrombose): caracterização e exploração fisiopatológica, diagnóstica e terapêutica em doenças infecciosas e inflamatórias |
| Beneficiário: | Erich Vinicius de Paula |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |